One of the challenges in drug development is making formulations that have a long-lasting therapeutic effect. Implantable products that release a drug slowly over time offer one way to deliver medication for longer than a day, but such long-acting effects have... Read more »
Food—it’s messy. It spoils. We don’t have time to cook it. We can’t live without it. These problems are catnip for hopeful tech startups looking for a business niche.
Here’s a fast wrap-up on food tech companies and what they’re serving... Read more »
[Updated 4/11/17, 9:44 a.m. See below.] Experimental drugs encounter their earliest tests in petri dishes and animals, but these tests can fall short of predicting what happens in humans. The life sciences industry has been pursuing what many hope... Read more »
In the nation’s capital, healthcare and life sciences were on center stage. Or stages, actually. On Capitol Hill, FDA commissioner nominee Scott Gottlieb, the drug industry’s favorite pick, told senators his extensive industry ties wouldn’t cloud his judgment or create conflicts.... Read more »
The American Association for Cancer Research held its annual meeting this week in Washington, DC, a convenient venue for former Vice President Joe Biden to deliver a broadside against the Trump administration’s proposed budget cuts in science funding.
For Biden, it’s... Read more »
Amid the ongoing conversation about gender discrimination in the tech industry, and recent sexual harassment claims against some of its biggest names, here’s some sort-of good news about women in tech:
When companies make job offers to both men and women,... Read more »
In what passes for a short hearing these days in Washington, DC, the Trump White House’s pick to run the Food and Drug Administration, Scott Gottlieb, spent less than three hours fielding questions from a Senate committee Wednesday morning.
Amid predictable... Read more »
Is a caution flag flying?
While U.S. venture firms refueled last year by raising a near-record $51.6 billion, they also eased off the throttle in terms of their investment activity during the first quarter of 2017, according to data released... Read more »
The need for new antibiotics to battle drug-resistant bacteria is rising, and Paratek Pharmaceuticals has news that could give doctors a new weapon.
Boston-based Paratek (NASDAQ: PRTK) reports that its antibiotic, omadacycline, has hit all its main and secondary goals... Read more »